Tsang JYS, et al. - Researchers examined β-amyloid precursor protein (APP) expression and its prognostic impact in different breast cancer subtypes in order to assess its clinical utility in breast cancers. Findings revealed a high expression of APP in nonluminal breast cancers and its correlation with features related to nonluminal breast cancers. In the nonluminal group, APP was identified as an independent adverse prognostic factor of disease-free survival and breast cancer-specific survival. In triple negative breast cancers, the independent prognostic effect was also evident. The results showed oncogenic roles of APP in clinical breast cancers. Vigilant monitoring of disease and more aggressive therapy may be needed in patients with positive APP expression, particularly those with APP upregulation in lymph node metastases.